Sudeep Pharma Limited has announced its Q2 financial results, revealing significant pressure on profitability metrics despite revenue growth. The pharmaceutical company's consolidated financial performance shows margin compression across key operational parameters during the quarter.

Financial Performance Overview

The company's Q2 results demonstrate challenging operational dynamics with declining profitability metrics. While revenue maintained positive momentum, both EBITDA and net profit faced substantial pressure during the reporting period.

EBITDA Performance Analysis

Sudeep Pharma's EBITDA declined significantly to ₹55.50 crores in Q2 compared to ₹63.50 crores in the corresponding quarter of the previous year. This represents a substantial decrease of ₹8.00 crores or 12.6% on a year-on-year basis, indicating operational challenges during the quarter.

Margin Compression Trends

The company's EBITDA margin contracted sharply to 34.09% in Q2 from 42.66% in the same quarter last year. This margin compression of 857 basis points reflects significant pressure on operational efficiency and cost management, despite the company's ability to grow its top-line revenue.

Revenue and Profitability Dynamics

Sudeep Pharma achieved revenue growth of 6.7% to ₹162.80 crores from ₹152.60 crores year-on-year. However, the company struggled to maintain profitability levels. The consolidated net profit declined to ₹45.70 crores compared to ₹48.70 crores in the previous year, representing a 6.2% decrease.

Key Financial Highlights

The Q2 results underscore the challenges facing the pharmaceutical company in maintaining operational efficiency amid revenue expansion. The significant EBITDA decline and margin compression suggest increased operational costs or pricing pressures that have impacted the company's profitability metrics during this reporting period.

Sudeep Pharma Limited has completed the publication of its Q2FY26 financial results extract in newspapers, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the results extract in Business Standard (English) and Vadodara Samachar (regional language) newspapers on December 20, 2025.

Regulatory Compliance

The company submitted the newspaper publication copies to both National Stock Exchange of India Limited and BSE Limited under Regulation 30 and 47 of SEBI (LODR) Regulations. Company Secretary Dimple Mehta confirmed that the financial results information is also available on the company's website at https://www.sudeeppharma.com/ .

Q2FY26 Financial Highlights

The published extract shows the company's consolidated financial performance for the quarter ended September 30, 2025:

Standalone Performance

On a standalone basis, the company reported total income from operations of ₹8,788.16 crores for Q2FY26 compared to ₹10,629.58 crores in the corresponding quarter of the previous year. Standalone profit after tax stood at ₹2,974.14 crores versus ₹2,945.04 crores in Q2FY25.

Board Approval and Corporate Information

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors in meetings held on December 18 and 19, 2025, respectively. The company operates from its registered office at GIDC Nandesari, Baroda, Gujarat, with corporate office at Gotri-Sevasi Road, Vadodara.

The complete financial results are available on stock exchange websites (BSE scrip code: 544619, NSE symbol: SUDEEPHRM) and the company's official website. A QR code has been provided in the published extract for easy access to the detailed financial statements.